Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis

PHASE3CompletedINTERVENTIONAL
Enrollment

335

Participants

Timeline

Start Date

May 8, 2019

Primary Completion Date

June 12, 2020

Study Completion Date

September 28, 2020

Conditions
Endometriosis
Interventions
DRUG

TAK-385

TAK-385 40 mg tablets + Leuprorelin acetate placebo injection

DRUG

Leuprorelin acetate

TAK-385 placebo tablets + Leuprorelin acetate 1.88 mg / 3.75 mg injection

Trial Locations (41)

Unknown

Chubu Rosai Hospital, Aichi

Meitetsu Hospital, Aichi

Aiiku Ladies Clinic, Chiba

Chiba Aoba Municipal Hospital, Chiba

Tokyo Bay Urayasu Ichikawa Medical Center, Chiba

Tsujinaka Hospital Kashiwanoha, Chiba

Fujito Clinic, Hiroshima

Hashimoto Clinic, Hokkaido

Tokeidai Memorial Hospital, Hokkaido

Yoshio Obstetrics Gynecology Hospital, Hokkaido

Shinsuma Hospital, Hyōgo

Kagawa Prefectural Central Hospital, Kagawa

Takamatsu Red Cross Hospital, Kagawa

Fujisawa City Hospital, Kanagawa

Rinkan Clinic, Kanagawa

Second Kawasaki Saiwai Clinic, Kanagawa

Tawada Ladies Clinic, Kanagawa

Japanese Red Cross Kumamoto Hospital, Kumamoto

Kurashiki Medical Clinic, Okayama

Chayamachi Ladies Clinic, Osaka

Hayakawa Clinic, Osaka

Minami-Morimachi Ladies Clinic, Osaka

Nomura Clinic Nanba, Osaka

Rikako Ladies Clinic, Osaka

Tanabe Ladies Clinic, Osaka

Yoshimura Ladies Clinic, Osaka

Dantsuka Clinic, Saitama

Kashiwazaki Ladies Clinic, Saitama

Maruyama Memorial General Hospital, Saitama

Kusatsu General Hospital, Shiga

Akasaka-Mitsuke Miyazaki Clinic, Tokyo

Ginza Yoshida Hospital, Tokyo

Hamada Hospital, Tokyo

Ikebukuro Metroporitan Clinic, Tokyo

NS Clinic, Tokyo

Sei Women's Clinic, Tokyo

Seijo Kinoshita Hospital, Tokyo

Shimamura Memorial Hospital, Tokyo

Toranomon Women's Clinic, Tokyo

Yokokura Clinic, Tokyo

Yukawa Women's Clinic, Tokyo

Sponsors
All Listed Sponsors
lead

ASKA Pharmaceutical Co., Ltd.

INDUSTRY